Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It offers Instaprin, a sublingual aspirin product that is a soluble, PH neutral, and fast acting aspirin, which addresses cardiology emergencies and pain management. The company is also developing formulations for sublingually administered products, including a melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide product. In addition, it is developing formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and other classes of drugs through sublingual administration; and caffeine products, such as a formula for a single dose sublingual pre-workout supplement. The company was founded in 2021 and is headquartered in Estero, Florida.

Employees - 2, CEO - Kraig T. Higginson, Sector - Healthcare, Country - US, Market Cap -

Altman ZScore(max is 10): -53.9, Piotroski Score(max is 10): 4, Working Capital: $-11457377, Total Assets: $2403129, Retained Earnings: $-22550347, EBIT: -25743495, Total Liabilities: $13870407, Revenue: $1941

AryaFin Target Price - $-0.04 - Current Price $ - Analyst Target Price $